Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -2.01 Million USD | 30.01% |
| 2021 | -2.87 Million USD | 0.06% |
| 2020 | -2.87 Million USD | -271.67% |
| 2019 | -774.82 Thousand USD | 7.41% |
| 2018 | -836.79 Thousand USD | 35.76% |
| 2017 | -1.3 Million USD | -23.65% |
| 2016 | -1.05 Million USD | -45.74% |
| 2015 | -722.85 Thousand USD | -2850.08% |
| 2014 | -24.5 Thousand USD | -68.35% |
| 2013 | -14.55 Thousand USD | -3.1% |
| 2012 | -14.11 Thousand USD | 18.58% |
| 2011 | -17.34 Thousand USD | 26.3% |
| 2010 | -23.52 Thousand USD | -46.86% |
| 2009 | -16.02 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q2 | -531.43 Thousand USD | -1.24% |
| 2022 Q1 | -524.94 Thousand USD | 21.42% |
| 2022 Q4 | -412.24 Thousand USD | 24.45% |
| 2022 Q3 | -545.68 Thousand USD | -2.68% |
| 2022 FY | -2.01 Million USD | 30.01% |
| 2021 Q2 | -553.7 Thousand USD | -7.76% |
| 2021 FY | -2.87 Million USD | 0.06% |
| 2021 Q4 | -668.07 Thousand USD | 41.51% |
| 2021 Q3 | -1.14 Million USD | -106.3% |
| 2021 Q1 | -513.85 Thousand USD | 72.45% |
| 2020 Q1 | -229.81 Thousand USD | -0.52% |
| 2020 Q2 | -310.59 Thousand USD | -35.15% |
| 2020 Q3 | -474.5 Thousand USD | -52.77% |
| 2020 Q4 | -1.86 Million USD | -293.01% |
| 2020 FY | -2.87 Million USD | -271.67% |
| 2019 Q1 | -212.35 Thousand USD | -19.87% |
| 2019 Q2 | -171.32 Thousand USD | 19.32% |
| 2019 Q3 | -162.51 Thousand USD | 5.15% |
| 2019 Q4 | -228.63 Thousand USD | -40.69% |
| 2019 FY | -774.82 Thousand USD | 7.41% |
| 2018 FY | -836.79 Thousand USD | 35.76% |
| 2018 Q4 | -177.15 Thousand USD | -22.48% |
| 2018 Q1 | -242.43 Thousand USD | 7.43% |
| 2018 Q2 | -272.57 Thousand USD | -12.43% |
| 2018 Q3 | -144.63 Thousand USD | 46.94% |
| 2017 FY | -1.3 Million USD | -23.65% |
| 2017 Q4 | -261.88 Thousand USD | 2.41% |
| 2017 Q3 | -268.36 Thousand USD | -7.25% |
| 2017 Q2 | -250.22 Thousand USD | 52.08% |
| 2017 Q1 | -522.15 Thousand USD | -51.03% |
| 2016 FY | -1.05 Million USD | -45.74% |
| 2016 Q1 | -219.33 Thousand USD | 68.47% |
| 2016 Q2 | -253.79 Thousand USD | -15.71% |
| 2016 Q3 | -234.6 Thousand USD | 7.56% |
| 2016 Q4 | -345.72 Thousand USD | -47.36% |
| 2015 Q1 | -7531.00 USD | -44.24% |
| 2015 Q2 | -7432.00 USD | 1.31% |
| 2015 Q3 | -12.31 Thousand USD | -65.66% |
| 2015 FY | -722.85 Thousand USD | -2850.08% |
| 2015 Q4 | -695.58 Thousand USD | -5549.63% |
| 2014 FY | -24.5 Thousand USD | -68.35% |
| 2014 Q2 | -8980.00 USD | -701.79% |
| 2014 Q4 | -5221.00 USD | 43.14% |
| 2014 Q1 | -1120.00 USD | 49.16% |
| 2014 Q3 | -9182.00 USD | -2.25% |
| 2013 Q2 | -7691.00 USD | -222.2% |
| 2013 Q1 | -2387.00 USD | 13.45% |
| 2013 Q3 | -2274.00 USD | 70.43% |
| 2013 Q4 | -2203.00 USD | 3.12% |
| 2013 FY | -14.55 Thousand USD | -3.1% |
| 2012 FY | -14.11 Thousand USD | 18.58% |
| 2012 Q4 | -2758.00 USD | -27.33% |
| 2012 Q3 | -2166.00 USD | -21.89% |
| 2012 Q1 | -7418.00 USD | -260.45% |
| 2012 Q2 | -1777.00 USD | 76.04% |
| 2011 Q1 | -7244.00 USD | 38.32% |
| 2011 Q3 | -6120.00 USD | -218.92% |
| 2011 Q2 | -1919.00 USD | 73.51% |
| 2011 FY | -17.34 Thousand USD | 26.3% |
| 2011 Q4 | -2058.00 USD | 66.37% |
| 2010 FY | -23.52 Thousand USD | -46.86% |
| 2010 Q4 | -11.74 Thousand USD | -37.3% |
| 2010 Q1 | -483.00 USD | -34.54% |
| 2010 Q3 | -8554.00 USD | -211.51% |
| 2010 Q2 | -2746.00 USD | -468.53% |
| 2009 Q4 | -359.00 USD | -14.7% |
| 2009 FY | -16.02 Thousand USD | 0.0% |
| 2009 Q3 | -313.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -308.876% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 78.837% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 93.284% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 97.0% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 87.286% |
| Better Therapeutics, Inc. | -38.26 Million USD | 94.736% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 95.212% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 83.172% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 94.048% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 94.148% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 98.143% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 94.076% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 95.71% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -47.31% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 89.898% |
| Molecular Templates, Inc. | -10.46 Million USD | 80.754% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 85.664% |
| NexImmune, Inc. | -29.19 Million USD | 93.1% |
| Orgenesis Inc. | -53.63 Million USD | 96.244% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 96.073% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -2481.876% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 87.524% |
| Scopus BioPharma Inc. | -11.71 Million USD | 82.806% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 99.601% |
| Statera Biopharma, Inc. | -98.34 Million USD | 97.952% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 70.799% |
| Trevena, Inc. | -35.28 Million USD | 94.292% |
| Vaxxinity, Inc. | -58.28 Million USD | 96.544% |
| Vaccinex, Inc. | -22.88 Million USD | 91.198% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -92.392% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 96.026% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 72.266% |